CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
Truvada (tenofovir/emtricitabine) +1 moredrug
Likely dose
Kaletra (lopinavir/ritonavir) 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00885664
NCT00885664Phase 4Completed
CompareCT.gov

Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection

University of Cincinnati·interventional·Posted Apr 22, 2009·Updated Aug 10, 2022

In Brief

A Phase 4 clinical trial evaluating Truvada (tenofovir/emtricitabine) and Kaletra (lopinavir/ritonavir) for HIV Infections. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The purposes of this study are: 1. To understand whether the use of HIV therapy in persons with more advanced HIV disease results in greater side effects. 2. To determine whether these side effects can be related to greater activation of the immune system.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
CollaboratorsAbbott, Gilead Sciences

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 22, 2009
Enrollment StartOct 1, 2005
Primary CompletionSep 1, 2009
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 17.2 years ago

Interventions

Truvada (tenofovir/emtricitabine)drug

Tenofovir/emtricitabine fixed dose combination once daily

Kaletra (lopinavir/ritonavir)drug

Lopinavir/ritonavir 400/100 mg twice daily